Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

CR-002

Other · developed by Crescent Biopharma

Phase 1/2 Most advanced trial
CBIO Developer
1 Registered trials

What is CR-002?

CR-002 is a drug studied in head and neck squamous cell carcinoma, gastric or gastroesophageal junction cancer, biliary tract cancer, esophageal squamous cell carcinoma, ovarian cancer, endometrial cancer, cervical cancer, and non-small cell lung cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Other
Therapy area
Oncology
Developer
Crescent Biopharma, Inc. (CBIO)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07909031 Phase 1/2 Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M) Recruiting CBIO

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Biliary Tract Cancer (BTC)Cervical Cancer MetastaticEndometrial CancerEsophageal Squamous Cell Carcinoma (ESCC)Gastric/GEJNon-small Cell Lung Cancer (NSCLC)Ovarian Cancer

More from Crescent Biopharma

Follow CBIO, the company behind CR-002

See CBIO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CBIO catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.